BofA analyst Geoff Meacham lowered the firm’s price target on Century Therapeutics to $20 from $23 and keeps a Buy rating on the shares. There were no surprises in Century’s Q4 print, says the analyst, who dropped the price target to reflect the Q4 financials and platform valuation.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IPSC:
- Century Therapeutics price target lowered to $17 from $19 at H.C. Wainwright
- Century Therapeutics reports FY22 EPS ($2.27), consensus ($2.32)
- Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
- Century Therapeutics to Present at the AACR Annual Meeting 2023
- Century Therapeutics to Present at Upcoming Investor Conferences
